NCT04059588: A Study Investigating the Safety and Tolerability of an Immune Treatment in Cancer Patients With Lesions to the Skin

NCT04059588
Breast Cancer Type: HER2+, HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older ¬† (Adult, Older Adult)
Location of Metastases: Skin
Additional Notes: 
Exclusions: Patients with known history of leptomeningeal leptomeningeal disease, metastases to the brain stem, midbrain, pons, or medulla, and/or metastases within 10 mm of the optic apparatus (optic nerve and chiasm)
https://ClinicalTrials.gov/show/NCT04059588

Comments are closed.

Up ↑